These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32425386)

  • 61. Iron overload in thalassemia: different organs at different rates.
    Taher AT; Saliba AN
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
    Taher AT; Cappellini MD; Aydinok Y; Porter JB; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Wang C; Zhu Z; Joaquin V; Uwamahoro MJ; Lai YR
    Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Challenges in transfusion and the role of Thalidomide in E-β-Thalassemia-A case report.
    Javed R; Radhakrishnan V; Basu S; Chandy M
    Clin Case Rep; 2020 Nov; 8(11):2208-2210. PubMed ID: 33235759
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pulmonary hypertension in non-transfusion-dependent thalassemia: Correlation with clinical parameters, liver iron concentration, and non-transferrin-bound iron.
    Inthawong K; Charoenkwan P; Silvilairat S; Tantiworawit A; Phrommintikul A; Choeyprasert W; Natesirinilkul R; Siwasomboon C; Visrutaratna P; Srichairatanakool S; Chattipakorn N; Sanguansermsri T
    Hematology; 2015 Dec; 20(10):610-7. PubMed ID: 25964094
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PlGF and sFlt-1 levels in patients with non-transfusion-dependent thalassemia: Correlations with markers of iron burden and endothelial dysfunction.
    Kelaidi C; Kattamis A; Apostolakou F; Poziopoulos C; Lazaropoulou C; Delaporta P; Kanavaki I; Papassotiriou I
    Eur J Haematol; 2018 Jun; 100(6):630-635. PubMed ID: 29543340
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.
    Bou-Fakhredin R; Bazarbachi AH; Chaya B; Sleiman J; Cappellini MD; Taher AT
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261151
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
    Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
    Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular understanding of Indian untransfused thalassemia intermedia.
    Nadkarni A; Dabke P; Colah R; Ghosh K
    Int J Lab Hematol; 2015 Dec; 37(6):791-6. PubMed ID: 26226914
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.
    Sleiman J; Tarhini A; Bou-Fakhredin R; Saliba AN; Cappellini MD; Taher AT
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316681
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network.
    De Sanctis V; Soliman A; Tzoulis P; Daar S; Kattamis A; Delaporta P; Karimi M; Yassin MA; Zarei T; Saki F; Sapunarova K; Banchev A; Galati MC; Raiola G; Messina G; Campisi S; Kattamis C
    Acta Biomed; 2022 May; 93(2):e2022162. PubMed ID: 35546014
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.
    Chaidos A; Makis A; Hatzimichael E; Tsiara S; Gouva M; Tzouvara E; Bourantas KL
    Acta Haematol; 2004; 111(4):189-95. PubMed ID: 15153710
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Thalidomide induces haematologic responses in patients with β-thalassaemia.
    Chen J; Zhu W; Cai N; Bu S; Li J; Huang L
    Eur J Haematol; 2017 Nov; 99(5):437-441. PubMed ID: 28850716
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Serum Levels of S100b and NSE Proteins in Patients with Non-Transfusion-Dependent Thalassemia as Biomarkers of Brain Ischemia and Cerebral Vasculopathy.
    Kanavaki A; Spengos K; Moraki M; Delaporta P; Kariyannis C; Papassotiriou I; Kattamis A
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29244749
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epidemiologic study of major complications in adolescent and adult patients with thalassemia in Northeastern Thailand: the E-SAAN study phase I.
    Teawtrakul N; Jetsrisuparb A; Pongudom S; Sirijerachai C; Chansung K; Wanitpongpun C; Fucharoen S
    Hematology; 2018 Jan; 23(1):55-60. PubMed ID: 28759343
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
    Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
    Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
    [No Abstract]   [Full Text] [Related]  

  • 77. Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later.
    Musallam KM; Cappellini MD; Viprakasit V; Kattamis A; Rivella S; Taher AT
    Am J Hematol; 2021 Feb; 96(2):E54-E56. PubMed ID: 33219703
    [No Abstract]   [Full Text] [Related]  

  • 78. Deferasirox: Over a Decade of Experience in Thalassemia.
    Moukalled NM; Bou-Fakhredin R; Taher AT
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018066. PubMed ID: 30416698
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
    Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
    N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Does Profile of Hemoglobin Eβ-thalassemia Patients Change After Splenectomy? Experience of a Tertiary Thalassemia Care Centre in Eastern India.
    Mandal PK; Ghosh MK; Bhattacharyya M
    Indian J Hematol Blood Transfus; 2015 Dec; 31(4):446-52. PubMed ID: 26306069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.